Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Shield Therapeutics PLC (STXS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.43 0.00    0.00%
16:35:59 - Closed. Currency in GBP ( Disclaimer )
  • Volume: 700,061
  • Bid/Ask: 1.35 / 1.55
  • Day's Range: 1.40 - 1.43
Type:  Equity
Market:  United Kingdom
ISIN:  GB00BYV81293 
SEDOL:  BYV8129
Shield Therapeutics 1.43 0.00 0.00%

Shield Therapeutics Company Profile

 
Read the Shield Therapeutics PLC company profile to learn more about the business and the management team. View Shield Therapeutics PLC facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

28

Equity Type

ORD

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Contact Information

Address Northern Design Centre Baltic Business Quarter
Gateshead, NE8 3DF
United Kingdom
Phone 44 1915 118 500
Fax -

Top Executives

Name Age Since Title
Hans-Peter Hasler 65 2018 Independent Non Executive Chairman
Rolf Karl-Heinz Hoffmann 62 2018 Independent Non-Executive Director
Peter Llewellyn-Davies - 2016 Independent Non-Executive Director
Christian Schweiger 55 2008 Co-Founder & Non Executive Director
Michael Stockham - - Notable Scientific Advisory Board
Christoph Gasche - - Notable Scientific Advisory Board
Jonathon Powell - - Notable Scientific Advisory Board
Gregory P. Madison 54 2021 CEO & Executive Director
Maria Fabiana Lacerca-Allen 54 2021 Independent Non-Executive Director
Anders Lundstrom 59 2021 Independent Non-Executive Director
Geoffrey A. Block 56 - Notable Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

STXS Price Commentary

Write your thoughts about Shield Therapeutics PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Craig Nelson
Craig Nelson Jul 28, 2023 16:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
11p needs to be back at 55p before considering selling
Anon Anon
Anon Anon Jul 21, 2023 9:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Sees strong prescription growth in the second quarter and first half of 2023. Total prescriptions for second quarter increase 50% to 15,800 compared to the first quarter. In first half of 2023, total prescriptions grow to around 26,300 which exceeds total prescription volumes for all of 2022. The company says that this growth in the first half means Shield is likely to meet its 2023 goal for US Accrufer prescriptions.
Paul ONeill
Paul ONeill Jun 07, 2023 13:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Check out takeover offer!
Anon Anon
Anon Anon Jun 07, 2023 13:14
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Don't take it up. It's a rip off
Craig Nelson
Craig Nelson May 05, 2023 10:01
Saved. See Saved Items.
This comment has already been saved in your Saved Items
7.48 why no good news from Sheild???
Antonis Pouppos
Antonis Pouppos Mar 21, 2023 9:48
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Totally agree, this stock is extremely undervalued, should Rushton 50p but patience is required
Craig Nelson
Craig Nelson Feb 10, 2023 8:37
Saved. See Saved Items.
This comment has already been saved in your Saved Items
7.26p this share s under performing...and needs to be back to the heady heights of 35p
Craig Nelson
Craig Nelson Aug 30, 2022 10:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Today 12p up 31%
Craig Nelson
Craig Nelson Aug 30, 2022 10:22
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why has this excellent share dropped so far off a cliff, surely 40p is its net asset value and then with markets opening in the US, a realistic price of 65p.
Craig Nelson
Craig Nelson Mar 10, 2022 0:21
Saved. See Saved Items.
This comment has already been saved in your Saved Items
18p
Craig Nelson
Craig Nelson Feb 19, 2022 8:44
Saved. See Saved Items.
This comment has already been saved in your Saved Items
21p well that's a shocker... And from being 15%up its now shocking... Has to be a BUY at 21p
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email